Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Science

Pharmaceutical

Research

Enodia Therapeutics

More Like This

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Argobio and the Institut Pasteur Launch Enodia Therapeutics: A Biotech Company With a New Approach for Targeted Protein Degradation

PR Newswire associated0

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

PR Newswire associated0

Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

PR Newswire associated0

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine